Navigation Links
Penn researchers discover new target for preventing and treating flu
Date:1/30/2008

PHILADELPHIA - Emerging subtypes of influenza A virus hold the potential to initiate a world-wide epidemic in the next few years, according to World Health Organization officials. However, almost all type A influenza viral strains have become resistant to amantadine and rimantadine, two drugs that make up one of only two classes used to treat the flu.

Researchers at the University of Pennsylvania School of Medicine have now provided a new strategy for designing drugs that target the resistant viral strains by solving the three-dimensional structure of a viral protein called the M2 proton channel. This protein is the molecular receptor for these drugs. This study is published in the Jan. 31 issue of the journal Nature.

The M2 protein is located in the viral envelope, forming a long, narrow channel that allows the flow of protons into the viral interior, an essential step for infection. Amantadine sits in this channel and blocks the flow of protons, thus halting infection. In non-resistant viruses, amantadine acts like a cork lodged deep in the channel.

We know that resistance to amantadine is caused by a mutation in the virus M2 protein, but we did not know how this mutation caused resistance, explains senior author William F. DeGrado, PhD, Professor of Biochemistry and Biophysics. Now we do the mutation changes the shape of the channel so amantadine can no longer do its job."

The structure revealed that there is a pocket in the channel next to the location where amantadine fits that is conserved in all influenza A viruses. This newly discovered space could be the target for new drugs. "Inhibitors that target this cavity adjacent to two highly conserved amino acids in M2 might reclaim the M2-blocking class of drugs so that ongoing endemic outbreaks and future pandemics of this deadly virus might be prevented and treated," says DeGrado.

"The crystal structures of influenza M2 with and without the anti-influenza drug help us understand the molecular basis of drug resistance, which is a serious problem in treating the flu," said Jean Chin, PhD, who oversees grants on membrane proteins at the National Institute of General Medical Sciences, which in part funded this research. "The findings will inform scientists working to design the next generation of antivirals."

The M2 protein was crystallized so that its structure could be examined under different conditions. This allowed the Penn research team, which included Amanda Stouffer, Rudresh Acharya, David Salom, Cinque Soto, Luigi Di Costanzo, Steven Stayrook, Vikas Nanda, and Anna Levine, to determine the structure of the crystallized protein using a technique called x-ray crystallography.

The pure protein crystal was bombarded with x-rays so that the position of each atom in relation to its neighboring atoms in the crystal would show up as an array of black spots. From the pattern of thousands of spots, the structure of the protein can be graphically visualized using computer imaging technology.

The next step is to design new compounds that plug the M2 channel by fitting into the newly discovered larger cavity. The Penn research group is currently engaged in these studies.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert  

Related medicine news :

1. Researchers investigate links between prostate, cadmium, zinc
2. New nanotube findings by Stanford researchers give boost to potential biomedical applications
3. Researchers Map Paths Governing Neuron Function
4. Cold Spring Harbor Laboratory researchers race against time to save Tasmanian devils
5. Researchers at Peoria Pulmonary Associates to study airway bypass procedure for emphysema
6. Pain medicine meeting unites top researchers and clinicians
7. Researchers identify brains eureka circuitry
8. Researchers find relief for chronic pain
9. Researchers propose consumers buy yearly drug licenses as new way to pay for prescriptions
10. Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
11. DOE awards supercomputing time to UCSD, SDSC researchers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Penn researchers discover new target for preventing and treating flu
(Date:8/17/2017)... ... August 17, 2017 , ... SeQuel Response announced today ... growth agency among the fastest-growing private companies in the U.S., putting it in the ... that have applied to the Inc. 5000 over the years, only a ...
(Date:8/17/2017)... Tree, CO (PRWEB) , ... August 17, 2017 , ... ... called Exilis in Lone Tree, CO, at Atagi Plastic Surgery and Skin Aesthetics. ... using a potent combination of radiofrequency and ultrasound energy. Smoother, younger-looking skin is revealed ...
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article on ... plastic surgery, largely influenced by the growing popularity of “pretty boys” in both K-Pop ... that standards of male appearance are changing not only in the Asian nation, where ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new devices, new features, ... changes to the smartwatch market. As of June 2017, nearly nine percent of U.S. ... months prior. Additionally, according to latest WEAR Report Industry Overview and Forecast from NPD’s ...
(Date:8/17/2017)... CO (PRWEB) , ... August 17, 2017 , ... ... Moral Injury: The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, ... (war) trauma, to encourage inner healing of memories and achieve forgiveness, through a ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... CAESAREA, Israel , August 17, 2017 /PRNewswire/ ... digital health Company with mobile health and big ... securities purchase agreements with domestic and non-U.S. investors ... common stock and shares of the Company,s newly ... private placement offerings. The Company expects to conduct ...
(Date:8/17/2017)... Aug. 17, 2017 Bio-Ess Laboratories, LLC Chief Science Officer, Dr. ... and present new data on Cell-Ess® Universal Titer Boost at ... Boston, MA August 21-25.  The Bioprocessing Summit convenes more than ... ... ...
(Date:8/15/2017)... , Aug. 15, 2017   Mostyn Law and Gulf ... Houston, Texas . The Mostyn Law family ... 2 years. That is why Mostyn Law is partnering ... to show its appreciation. Blood supplies are running ... 5% short of hospital needs in August. That is why the ...
Breaking Medicine Technology: